Department of Pediatrics & Child Health and Department of Immunology, Faculty of Medicine, University of Manitoba, Room FE125, 820 Sherbrook Street, Winnipeg, Manitoba, Canada, R3A 1R9.
Cátedra Neumonología, Alergia e Inmunología, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina.
World Allergy Organ J. 2014 May 30;7(1):9. doi: 10.1186/1939-4551-7-9. eCollection 2014.
Anaphylaxis provides a unique perspective on the principal evidence-based anaphylaxis guidelines developed and published independently from 2010 through 2014 by four allergy/immunology organizations. These guidelines concur with regard to the clinical features that indicate a likely diagnosis of anaphylaxis -- a life-threatening generalized or systemic allergic or hypersensitivity reaction. They also concur about prompt initial treatment with intramuscular injection of epinephrine (adrenaline) in the mid-outer thigh, positioning the patient supine (semi-reclining if dyspneic or vomiting), calling for help, and when indicated, providing supplemental oxygen, intravenous fluid resuscitation and cardiopulmonary resuscitation, along with concomitant monitoring of vital signs and oxygenation. Additionally, they concur that H1-antihistamines, H2-antihistamines, and glucocorticoids are not initial medications of choice. For self-management of patients at risk of anaphylaxis in community settings, they recommend carrying epinephrine auto-injectors and personalized emergency action plans, as well as follow-up with a physician (ideally an allergy/immunology specialist) to help prevent anaphylaxis recurrences. ICON: Anaphylaxis describes unmet needs in anaphylaxis, noting that although epinephrine in 1 mg/mL ampules is available worldwide, other essentials, including supplemental oxygen, intravenous fluid resuscitation, and epinephrine auto-injectors are not universally available. ICON: Anaphylaxis proposes a comprehensive international research agenda that calls for additional prospective studies of anaphylaxis epidemiology, patient risk factors and co-factors, triggers, clinical criteria for diagnosis, randomized controlled trials of therapeutic interventions, and measures to prevent anaphylaxis recurrences. It also calls for facilitation of global collaborations in anaphylaxis research. IN ADDITION TO CONFIRMING THE ALIGNMENT OF MAJOR ANAPHYLAXIS GUIDELINES, ICON: Anaphylaxis adds value by including summary tables and citing 130 key references. It is published as an information resource about anaphylaxis for worldwide use by healthcare professionals, academics, policy-makers, patients, caregivers, and the public.
过敏反应为我们提供了一个独特的视角,让我们能够从四大过敏/免疫学组织于 2010 年至 2014 年分别独立制定和发布的主要基于循证的过敏反应指南中,一窥全貌。这些指南在预示过敏反应可能发生的临床特征方面达成一致——即危及生命的全身性或系统性过敏或过敏样反应。它们还就初始治疗方案达成一致,即通过大腿中部肌肉注射肾上腺素(即: 皮下注射),使患者保持仰卧位(如果呼吸困难或呕吐,则采取半卧位),呼救,并在需要时提供补充氧气、静脉补液复苏和心肺复苏,同时对生命体征和氧合情况进行监测。此外,它们还一致认为 H1 抗组胺药、H2 抗组胺药和糖皮质激素不是初始治疗药物。对于社区环境中存在过敏反应风险的患者的自我管理,它们建议携带肾上腺素自动注射器和个性化紧急行动计划,并由医生(理想情况下是过敏/免疫学专家)进行后续跟进,以帮助预防过敏反应再次发生。ICON:过敏反应描述了过敏反应领域存在的未满足需求,指出虽然全球范围内都可获得 1 毫克/毫升安瓿装肾上腺素,但其他必需品,包括补充氧气、静脉补液复苏和肾上腺素自动注射器,并非普遍可得。ICON:过敏反应提出了一项全面的国际研究议程,呼吁对过敏反应流行病学、患者风险因素和共病因素、触发因素、诊断临床标准、治疗干预措施的随机对照试验以及预防过敏反应复发的措施进行更多前瞻性研究。它还呼吁促进过敏反应研究的全球合作。除了确认主要过敏反应指南的一致性外,ICON:过敏反应还通过包含总结表和引用 130 个关键参考文献来增加价值。它作为过敏反应的信息资源发布,供全球医疗保健专业人员、学者、政策制定者、患者、护理人员和公众使用。